|
Therapeutic antibodies have shown immense success in the marketplace and drug development pipelines are increasingly dominated by them. However, due to the requirement of a high therapeutic dose antibodies are often administered by slow intravenous infusions taking several hours and necessitating the involvement of local hospitals. This is not only inconvenient for patients but localizes administration to clinical settings which can be costly.
A number of big pharmaceutical and biotechnology companies are presently seeking novel ways of increasing the therapeutic dose for their proprietary antibodies to levels as high as 50-200 mg/ml. Through the application of Arestat™ technologies, Arecor has demonstrated that higher concentrations of proteins can be maintained in storage without degradation or aggregation typically associated with such formulations. Arecor is working with a range of approved recombinant therapeutic proteins at significantly higher doses than the marketed brands thereby creating opportunities for new routes of administration for these formulations. |
|
ArestatTM comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability
Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics
|
